Ola Adebayo
Overview
Explore the profile of Ola Adebayo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun J, Corradini S, Azab F, Shokeen M, Muz B, Miari K, et al.
Leukemia
. 2024 Aug;
38(11):2355-2365.
PMID: 39215060
Multiple myeloma (MM) is the cancer of plasma cells within the bone marrow and remains incurable. Tumor-associated macrophages (TAMs) within the tumor microenvironment often display a pro-tumor phenotype and correlate...
2.
Sun J, Park C, Guenthner N, Gurley S, Zhang L, Lubben B, et al.
J Immunother Cancer
. 2022 Apr;
10(4).
PMID: 35428704
Multiple myeloma (MM) is a cancer of plasma cells in the bone marrow (BM) and represents the second most common hematological malignancy in the world. The MM tumor microenvironment (TME)...
3.
Sun J, Chen Y, Lubben B, Adebayo O, Muz B, Azab A
Leuk Res Rep
. 2021 Sep;
16:100268.
PMID: 34584838
CD47 is a surface glycoprotein expressed by host cells to impede phagocytosis upon binding to macrophage SIRPα, thereby represents an immune checkpoint known as the "don't-eat-me" signal. However, accumulating evidence...
4.
Alhallak K, Sun J, Muz B, Jeske A, Yavner J, Bash H, et al.
Oncotarget
. 2021 Sep;
12(19):1878-1885.
PMID: 34548905
Acute myeloid leukemia (AML) is the most common type of leukemia and has a 5-year survival rate of 25%. The standard-of-care for AML has not changed in the past few...
5.
Alhallak K, Sun J, Jeske A, Park C, Yavner J, Bash H, et al.
Cancers (Basel)
. 2021 Jul;
13(12).
PMID: 34201007
MM is the second most common hematological malignancy and represents approximately 20% of deaths from hematopoietic cancers. The advent of novel agents has changed the therapeutic landscape of MM treatment;...